Report #2858039

Received Sep 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 71 yrs
State: ME
Recovered: Unknown
Vaccinated: Sep 2, 2025
Onset: Sep 2, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

had her first dose of Shingrix, administered in 2018 and her second dose administered on 02-SEP-2025 longer than recommended interval; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in 2018). Concomitant products included Fluconazole (Flu). On 02-SEP-2025, the patient received the 2nd dose of Shingrix. On 02-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: had her first dose of Shingrix, administered in 2018 and her second dose administered on 02-SEP-2025 longer than recommended interval). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 04-SEP-2025 The patient self-reported this case for herself.

Other medications

Flu